Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003147963 | SCV003835471 | uncertain significance | Lichtenstein-Knorr syndrome | 2022-10-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004246149 | SCV004953011 | uncertain significance | not specified | 2023-12-20 | criteria provided, single submitter | clinical testing | The c.176A>T (p.D59V) alteration is located in exon 1 (coding exon 1) of the SLC9A1 gene. This alteration results from a A to T substitution at nucleotide position 176, causing the aspartic acid (D) at amino acid position 59 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004790491 | SCV005410489 | uncertain significance | not provided | 2024-09-13 | criteria provided, single submitter | clinical testing | BP4, PM2 |